MetaVia Inc.
MTVA
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.33M
Close$
Share Statistics
| Market cap | $20.33 Million |
|---|---|
| Enterprise Value | $7.88 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -211.76% |
|---|---|
| Return on Assets | -108.85% |
| Return on Invested Capital | -217.03% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.52 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About NeuroBo Pharmaceuticals Inc
8 employees
CEO: Hyung Heon Kim Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading inv...